Thus, abrogation of G2/M checkpoint via the inhibition of CHK1 activity could provide an optimal therapeutic route to selectively sensitize tumor cells to chemotherapy and remove subsequent resistance mechanisms. This evidence concerns the gene CHEK1 and neoplasm.